Vapotherm, Inc.
13
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
30.8%
4 terminated/withdrawn out of 13 trials
63.6%
-22.9% vs industry average
0%
0 trials in Phase 3/4
114%
8 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
HVNI vs NIPPV in Type 2 Respiratory Failure
Role: collaborator
Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline
Role: lead
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
Role: lead
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
Role: lead
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Device Equivalence
Role: lead
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
Role: lead
Non-Inferiority Trial of Acute HFT Versus nCPAP
Role: lead
Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)
Role: collaborator
Oxygen Assist Module in Preterm Infants on High Flow Nasal Cannula Support.
Role: collaborator
HVNI Ambulation Feasibility Study
Role: lead
High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)
Role: lead
High Flow Therapy for the Treatment of Respiratory Failure in the ED
Role: lead
IntellO2 vs Manual Control for Optimizing Oxygenation in Infants
Role: lead
All 13 trials loaded